First AD

Second AD

Sequence 01.00_00_04_23.Still002.png

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Optimizing Therapy for Patients with Acute and Chronic Graft-Versus-Host Disease (GvHD)

Peer Exchange

Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025. 

Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

Optimal First-Line Treatment Approaches for Acute GvHD

Treatment Options in Steroid-Refractory Acute GvHD

Enhancing Patient Care in Acute GvHD: Supportive Measures

Advancements and Promising Directions in Acute GvHD

Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

A Comprehensive Look at Initial Treatment Options for Chronic GvHD

Data-Driven Treatment Selection for Patients with Chronic GvHD

Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

The Future of Chronic GvHD Treatment

Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma 

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC